In contrast with the previous observations and in line with our results, ibrutinib (but not acalabrutinib) increased CD4+ and CD8+ T cells in CLL patients (more prominently in the effector/effector memory subsets), as a result of the diminished activation-induced cell death through ITK inhibition. This evidence concerns the gene CD4 and B-cell chronic lymphocytic leukemia.